Efficacy of Taletrectinib (AB-106/DS-6051b) in ROS1+ NSCLC: An Updated Pooled Analysis of U.S. and Japan Phase 1 Studies

INTRODUCTION: Taletrectinib (AB-106/DS-6051b) is an oral, potent selective ROS1 and pan-NTRK tyrosine kinase inhibitor (TKI). Preclinically, taletrectinib has activity against ROS1 G2032R solvent-front mutation. METHODS: Patients with ROS1+ NSCLC enrolled into two phase 1 studies conducted in United...

Descripción completa

Detalles Bibliográficos
Autores principales: Ou, Sai-Hong Ignatius, Fujiwara, Yutaka, Shaw, Alice T., Yamamoto, Noboru, Nakagawa, Kazuhiko, Fan, Frank, Hao, Yuki, Gao, Yanfei, Jänne, Pasi A., Seto, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474193/
https://www.ncbi.nlm.nih.gov/pubmed/34589973
http://dx.doi.org/10.1016/j.jtocrr.2020.100108

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474193/
https://www.ncbi.nlm.nih.gov/pubmed/34589973
http://dx.doi.org/10.1016/j.jtocrr.2020.100108

Ejemplares similares